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Abstract Background: Large quantities of cell-free foetal
DNA have been detected in amniotic ﬂuid, and it has
been proposed that this material may contribute to the
pool of cell-free foetal DNA in maternal plasma.
Methods: Twelve maternal blood samples were obtained
from pregnant women about to undergo an amniocen-
tesis. Cell-free DNA was extracted from the maternal
plasma samples and the matched amniotic ﬂuid samples.
The amount of cell-free foetal DNA was quantiﬁed by
real-time PCR assays for the SRY and RHD genes.
Results: Amniotic ﬂuid was found to contain vast
quantities of cell-free DNA (median concentration =
3,978 copies/ml amniotic ﬂuid). The concentration of
cell-free foetal DNA in maternal plasma was much
lower (median concentration = 96.6 copies/ml maternal
plasma). No signiﬁcant correlation could, however, be
determined between these two pools of cell-free foetal
DNA. Conclusions: Our data conﬁrm that amniotic ﬂuid
contains prodigious quantities of cell-free foetal DNA,
but as no relationship exists between this material and
that in the maternal circulation, it is unlikely that the
amnion contributes to the presence of cell-free foetal
DNA in maternal plasma.
Introduction
The analysis of cell-free foetal DNA in maternal
plasma or serum is rapidly gaining in importance as a
new method for the prenatal diagnosis of foetal genetic
loci, particularly for the determination of the foetal
Rhesus status and sex, in pregnancies at risk for an
X-linked disorder [1, 2]. Consequently, commercial
services are already being oﬀered in Europe for the
latter two applications [3, 4]. Furthermore, quantitative
analysis of cell-free foetal DNA concentrations in
maternal plasma have indicated that these are elevated
in pregnancies at risk or aﬀected by pre-eclampsia [5,
6], those with preterm labour [7], as well as those with
aneuploid foetuses, particularly those with trisomy 21
[8, 9]. These ﬁndings have suggested that cell-free
foetal DNA may serve as a potential marker to screen
for such pregnancies [2, 10].
A current dilemma, especially with regard to the
latter application, is that it is currently not clear what
the origin of cell-free foetal DNA in the maternal cir-
culation is [11]. This knowledge is of considerable
importance, especially when dealing with disorders
having an underlying placental aetiology such as pre-
eclampsia, in that it would be best if the new marker
studied would somehow reﬂect upon the causal pathol-
ogy, rather than just be a secondary consequence of it, as
the latter would reduce the speciﬁcity of the new test.
Although the most likely source of the pool of cell-
free foetal DNA in maternal plasma is the placenta, this
remains to be conclusively proven. Data supporting the
placental origin of this foetal material include the rapid
disappearance of cell-free foetal DNA from the maternal
circulation following delivery and removal of the pla-
centa [12], as well as the association of cell-free foetal
DNA molecules with placentally derived microparticles
[13]. Furthermore, cases of placental mosaicism have
been shown to be associated with the lack of particular
foetal genetic loci in the cell-free fraction of foetal DNA
in maternal plasma [14].
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On the other hand, it has been suggested that this cell-
free foetal material could be derived from the apoptotic
demise of foetal cells which have entered the maternal
circulation [15]. This scenario does not appear to be very
likely, as the quantity of cell-free foetal DNA in maternal
plasma is at least 100-fold higher than the number of
foetal cells present in the maternal circulation [16]. Fur-
thermore, even short-lived foetal cells such as erythro-
blasts are present in the maternal circulation for several
weeks post partum, during which period no traces of cell-
free foetal DNA exist anymore. In addition, we have
previously shown that elevations in cell-free foetal DNA
can occur under conditions, such as preterm labour,
which are not associated with an elevated traﬃcking of
foetal cells [17]. This latter ﬁnding strongly suggests that
the two entities, circulating foetal cells and cell-free foetal
DNA, are not casually related [18].
Recently, however, a very intriguing other possibil-
ity has been suggested, namely amniotic ﬂuid, which
was found to contain copious amounts of cell-free
foetal DNA [19]. In order to test this pertinent
hypothesis, we studied cell-free foetal DNA levels in 12
individually matched amniotic ﬂuid and maternal
blood samples.
Materials and methods
Sample recruitment and processing
Approval for the study was granted by our institutional
review board and written informed consent was ob-
tained in all instances. All maternal blood samples
(15 ml EDTA) were obtained immediately prior to
amniocentesis. The median gestational age was
15.1 weeks. Amniotic ﬂuid samples were collected from
the washing steps conducted prior to the amniotic cells
being placed into culture at the Department of Medical
Genetics, University Clinics, Basel, Switzerland.
Both the plasma samples and amniotic ﬂuid were
cleared by high-speed centrifugation in a microcentri-
fuge (12,000 g for 10¢) and the supernatant was carefully
removed, to ensure that no cellular debris was carried
over. DNA was prepared from these samples using
commercial column technology (Qiagen, Basel, Swit-
zerland) according to a protocol well established in our
laboratory [9]. For the analysis of maternal plasma,
800 ll was extracted and eluted into 50 ll elution buﬀer,
5 ll was used per PCR reaction. For the analysis of
amniotic ﬂuid, 400 ll was extracted and eluted into
50 ll elution buﬀer, 5 ll was used per PCR reaction.
Real-time PCR analysis
The concentration of cell-free foetal DNA in these
amniotic ﬂuid or plasma samples using real-time PCR
assays speciﬁc for the SRY gene on the Y chromosome,
as well as the foetal Rhesus D gene in Rhesus D negative
pregnant women, using protocols well established in our
laboratory [20]. The dual labeled-probe and primer se-
quences were as follows:
FAM is 6-carboxyﬂuorescein, TAMRA is 6-carb-
oxytetramethylrhodamine and VIC is a registered
trademark of Applied Biosystems.
For the TaqMan PCR analysis, we used 25 lL
reaction volumes containing 5 lL of the extracted
DNA, 300 nM of each ampliﬁcation primer and
100 nM of the dual-labelled TaqMan probe. The reac-
tion mixture containing the necessary components pro-
vided in the TaqMan PCR Core reaction Kit (Perkin
Elmer, Branchburg, NJ), contained 2.5 lL of 10· Buﬀer
A, 3.5 mM MgCl2, 100 lM dNTPS, 0.025 U/lL Amp-
liTaq Gold and 0.01 U/lL Amp Erase. The ampliﬁca-
tion runs were carried out using a 2 min incubation at
50C, to permit Amp Erase activity, followed by an
initial denaturation step at 95C for 10 min, which
facilitates activation of the AmpliTaq Gold polymerase
activity, followed by 40 cycles of 1 min at 60C and 15 s
at 95C.
Statistical analysis
To determine whether any signiﬁcant correlation be-
tween the levels of cell-free foetal DNA in maternal
plasma and the amount of cell-free foetal DNA in the
corresponding sample of amniotic ﬂuid this was tested
using Spearman´s coeﬃcient of rank correlation. All
calculations were performed using the statistical package
for social sciences (SPSS for Windows 10.0).
SRY:
Forward: 5¢ TCC TCA AAA GAA ACC GTG CAT 3¢
Reverse: 5¢ AGA TTA ATG GTT GCT AAG GAC TGG AT 3¢
Probe: 5¢ (FAM) CAC CAG CAG TAA CTC CCC ACA ACC TCT TT (TAMRA) 3¢
RhD:
Forward: 5¢ CCT CTC ACT GTT GCC TGC ATT 3¢
Reverse: 5¢ AGT GCC TGC GCG AAC ATT 3¢
Probe: 5¢ (VIC) TAC GTG AGA AAC GCT CAT GAC AGC AAA GTC T (TAMRA) 3¢
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Results
Our study indicated that Y speciﬁc sequences could be
detected in both the amniotic ﬂuid and plasma samples
in 7 of the cases examined. This correlated very well with
the foetal sex, as only 7 of the 12 cases were male. No
false positive results were recorded in those 5 cases with
female foetuses. Our analysis conﬁrmed that very high
levels of cell-free foetal DNA were indeed present in the
amniotic ﬂuid (Table 1). In one instance, we noted an
exceptionally high concentration of cell-free foetal DNA
of 821,994 copies/ml amniotic ﬂuid. The exclusion or
inclusion of this apparent outlier did not signiﬁcantly
alter any of the subsequent statistical analysis. The
analysis of the remaining samples indicated that
the median concentration of cell-free foetal DNA in the
amniotic ﬂuid was 3,978 copies/ml amniotic ﬂuid (range
= 255–26,019 copies/ml). In the corresponding mater-
nal plasma samples, we determined a median cell-free
foetal DNA concentration of 96.9 copies/ml maternal
plasma (range = 13–286 copies/ml maternal plasma).
As these samples had been obtained from Rhd
pregnant women, we also examined the levels of cell-free
foetal DNA using a real-time assay for the RhD gene.
This analysis indicated that 9 of the 12 foetuses had an
RhD genotype, which was in good agreement with the
analysis from the clinical laboratory. In one case, which
was scored by our examination of both maternal plasma
and amniotic ﬂuid as an Rhd negative foetus, no clinical
outcome regarding the foetal Rhesus genotype was
available (Table 1). In our analysis of the other cases,
the median concentration of cell-free foetal DNA in the
amniotic ﬂuid was 23,707 copies/ml amniotic ﬂuid
(range = 229–811078 copies/ml). In the corresponding
maternal plasma samples, we determined a median cell-
free foetal DNA concentration of 161 copies/ml mater-
nal plasma (range = 39–600 copies/ml maternal plas-
ma).
Our analysis indicated a very good degree of corre-
lation between the levels of SRY-positive and
RhD-positive cell-free foetal DNA in maternal plasma
(r=0.2; P=0.67; n=5; Fig. 1a), as well as in amniotic
ﬂuid (r=0.2; P=0.67; n=5; Fig. 1b).
We next examined whether a correlation existed be-
tween the amount of cell-free foetal DNA in the amni-
otic ﬂuid to the matched plasma samples by Spearman
rank analysis, which indicated that no signiﬁcant cor-
relation was present for SRY-positive cell-free foetal
DNA (r=0.2; P=0.67; n=7) or RhD-positive cell-free
foetal DNA (r=0.02; P=0.95; n= 8) (Fig. 2a, b).This
feature was true even when a combined analysis of both
foetal loci was performed (r=0.2; P=0.67; n=15).
Discussion
Our data conﬁrm that amniotic ﬂuid contains copious
amounts of cell-free foetal DNA [19], and that this is
true for multiple foetal loci, such as the SRY and RhD
genes. In our analysis we have examined whether this
rich pool of cell-free foetal DNA contributes to that in
the maternal circulation, using these two foetal loci. Our
data, obtained for 7 cases analysed by a Taqman real-
time PCR assay for the SRY gene and 8 cases examined
by a Taqman real-time PCR for the SRY gene, suggests
that no relationship exists between the pool of cell-free
DNA in the amniotic ﬂuid and that in the maternal
circulation. Therefore, it appears unlikely that the am-
nion contributes to the amount of cell-free foetal DNA
in the maternal circulation.
Although it might be argued that an asynchronous
relationship might exist by the intermittent perfusion of
cell-free DNA from the amnion across the placenta into
the periphery. However, as it has previously been shown
that the cell-free foetal DNA in the maternal peripheral
circulation has a very short half life in the order of
15 min [12], this latter scenario appears to be rather
unlikely.
Since it also appears unlikely that traﬃcking foetal
cells contribute signiﬁcantly to the level of cell-free foetal
DNA in the maternal circulation, in that cell-free foetal
Table 1 Levels of cell-free cell-
free foetal DNA levels in
amniotic ﬂuid and matched
maternal plasma samples
Concentration of foetal DNA
is given in copies/ml maternal
plasma
aNo clinical outcome for the
foetal RhD status could be
obtained for this sample
ID Concentration of cell-free foetal
DNA in amniotic ﬂuid
Concentration of cell-free
foetal DNA in maternal
plasma
SRY RhD SRY RhD
1 6878 0a 124.5 0a
2 26018 23706 149 130
3 0 0 0 0
4 0 43429 0 178
5 0 44600 0 112
6 1078 1636.5 286 246
7 347 229 31 39
8 821942 811078 259 254
9 0 425404 0 161
10 255 0 69 0
11 0 829 0 600
12 7302 8176.5 13 0
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DNA levels can be elevated under conditions, such as
preterm labour, where foetal cell traﬃc is not altered [17,
18], the question arises where this cell-free foetal genetic
material stems from.
Although it remains to be conclusively proven, it
appears that the placenta is the most likely source [21].
This is supported by evidence that cell-free foetal DNA
is rapidly removed from the maternal circulation
following delivery [12]. This hypothesis is further
supported by reports indicating that placental mosai-
cism is reﬂected by absence of the same foetal genetic
locus in the cell-free portion of foetal DNA in the
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Fig. 1 Signiﬁcant correlation
between SRY and RhD positive
cell-free foetal DNA levels in
maternal plasma or amniotic
ﬂuid. a Cell-free foetal DNA
levels in maternal plasma. b
Cell-free foetal DNA levels in
amniotic ﬂuid. Concentration
of foetal DNA is given in
copies/ml maternal plasma
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maternal circulation [14]. In addition, cell-free foetal
DNA is associated with placental microparticles of
syncytiotrophoblast origin [13]. Possibly, the ﬁnal proof
will be obtained by studying foetal genetic loci which are
epigenetically modiﬁed in the placenta [22].
Once this question has been irrevocably addressed, it
will to be elucidated how cell-free foetal DNA is liber-
ated by this organ, and how this process is disturbed in
various pregnancy related disorders, particularly hose of
pre-eclampsia and preterm labour [21]. Such knowledge
may increase our understanding of the underlying
aetiologies of these enigmatic disorders, which still
present a considerable clinical challenge.
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